Notice of Allowability	Application No.	Applicant(s)
	10/632,599	HU, MIN Art Unit
Notice of Allowability	Examiner	Art Onit
	Michael C. Henry	1623
The MAILING DATE of this communication appearance All claims being allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIOF the Office or upon petition by the applicant. See 37 CFR 1.313	(OR REMAINS) CLOSED in this apport or other appropriate communication (GHTS. This application is subject to	olication. If not included will be mailed in due course. <b>THIS</b>
1. This communication is responsive to <u>12/03/04</u> .		
2. X The allowed claim(s) is/are 13 and 14. These claims are re	numbered 1 and 2, respectively.	
3. $\boxtimes$ The drawings filed on <u>12 August 2003</u> are accepted by the	Examiner.	
4. ☐ Acknowledgment is made of a claim for foreign priority under a) ☐ All b) ☐ Some* c) ☐ None of the:  1. ☐ Certified copies of the priority documents have 2. ☐ Certified copies of the priority documents have 3. ☐ Copies of the certified copies of the priority documents have International Bureau (PCT Rule 17.2(a)).  * Certified copies not received:  Applicant has THREE MONTHS FROM THE "MAILING DATE"	been received. been received in Application No cuments have been received in this of this communication to file a reply	national stage application from the
noted below. Failure to timely comply will result in ABANDONN THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.  5. A SUBSTITUTE OATH OR DECLARATION must be submin INFORMAL PATENT APPLICATION (PTO-152) which give	itted. Note the attached EXAMINER	'S AMENDMENT or NOTICE OF tion is deficient.
6. CORRECTED DRAWINGS ( as "replacement sheets") mus  (a) including changes required by the Notice of Draftspers  1) hereto or 2) to Paper No./Mail Date  (b) including changes required by the attached Examiner's Paper No./Mail Date  Identifying Indicia such as the application number (see 37 CFR 1 each sheet. Replacement sheet(s) should be labeled as such in the state of the property of the state of the sheet of the state of the s	st be submitted. son's Patent Drawing Review ( PTO s Amendment / Comment or in the C .84(c)) should be written on the drawing to 37 CFR 1.121(c)	948) attached  Office action of the back) of d).
<ol> <li>DEPOSIT OF and/or INFORMATION about the depo attached Examiner's comment regarding REQUIREMENT</li> </ol>	sit of BIOLOGICAL MATERIAL r FOR THE DEPOSIT OF BIOLOGIC	nust be submitted. Note the AL MATERIAL.
Attachment(s) 1. ☐ Notice of References Cited (PTO-892)	5. Notice of Informal P	atent Application (PTO-152)
Notice of Preferences Cited (170-032)     Notice of Draftperson's Patent Drawing Review (PTO-948)	6. Interview Summary	
Information Disclosure Statements (PTO-1449 or PTO/SB/C Paper No./Mail Date	Paper No./Mail Dai	te
4. Examiner's Comment Regarding Requirement for Deposit		ent of Reasons for Allowance  JAMES 0. WILSON
of Biological Material	9.  Other SUP	ERVISORY PATENT EXAMINER ECHNOLOGY CENTER 7600

U.S. Patent and Trademark Office PTOL-37 (Rev. 1-04)

Part of Paper No./Mail Date 20050310

Application/Control Number: 10/632,599

Art Unit: 1623

## EXAMINER'S AMENDMENT/REASONS FOR ALLOWANCE

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

The application has been amended as follows:

Claims 1-12 (canceled).

Claims 15-23 (canceled).

The following is an examiner's statement of reasons for allowance: The examiner has found claims 13 and 14 to be unobvious over the prior art of record and therefore to be allowable over the prior art of record. The present invention relates to a method of promoting wound healing in a subject, said method comprising administering to said subject a composition comprising: a multi-layered glycosaminoglycan structure, wherein said glycosaminoglycan structure comprises a core of free glycosaminoglycan, a layer of crosslinked glycosaminoglycan strands surrounding said core; a charged molecule surrounding said layer of crosslinked glycosaminoglycan strands; and an excipient. The invention also relates to a method of treating a glycosaminoglycan-mediated condition in a subject with said composition. The very relevant prior art documents (US 5,510,328 and US 5,766,631) to this invention discloses a method of promoting wound healing (by reducing and inhibiting wound contraction) in a subject, and discloses compositions for treating wounds, but neither documents (singly or in combination) disclose or suggest the use of the multi-layered glycosaminoglycan structure of the instant invention to promote wound healing or to treat a glycosaminoglycan-mediated condition.

Page 3

Application/Control Number: 10/632,599

Art Unit: 1623

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

## Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Michael C. Henry whose telephone number is 571-272-0652. The examiner can normally be reached on 8:30 am to 5:00 pm; Mon-Fri. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James O. Wilson can be reached on 571-272-0661. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703 308-1235.

**MCH** 

March 11, 2005.

JAMES O. WILSON

SUPERVISORY PATENT EXAMINER

TECHNOLOGY CENTER 1600